Internship

Summer 2024 – Commercial Data Science Internship

Posted on 2/29/2024

Bristol Myers Squibb

Bristol Myers Squibb

10,001+ employees

Develops and delivers biopharmaceutical medicines

Compensation Overview

$25 - $29/hr

Company Historically Provides H1B Sponsorship

Princeton, NJ, USA

Physical presence at the BMS worksite or physical presence in the field is a necessary job function of this role, which the Company deems critical to collaboration, innovation, productivity, employee well-being and engagement, and it enhances the Company culture.

Category
AI & Machine Learning
Data & Analytics
Required Skills
Python
Data Science
Tensorflow
R
Git
Pytorch
SQL
Tableau
Marketing
Natural Language Processing (NLP)
Requirements
  • Currently enrolled in BA/BS degree (quantitative area of study preferred)
  • Experience with Git is preferred
  • Experience with data science Python/R libraries (e.g., scikit-Learn, Tensorflow or Pytorch) is preferred
  • Familiarity with model explainability tools such as shap or lime
  • 0-1+ years of Analytical Experience
  • Proficiency in Python/R, SQL, Tableau and MS Office Suite
Responsibilities
  • Translate the complexity of the models in business language to make the insights understood better and drive the use of these models further
  • Be experienced in NLP techniques and how they can be leveraged to solve business problems
  • Understand promotional channels and marketing mix for commercialization within the pharmaceutical industry
  • Understand BMS’s commercialized products and relevant indications
  • Support implementation of tools to facilitate the data visualization (Tableau, R-Shiny, Dash)
  • Develop, review, and validate SQL to generate Datasets, Tables and Figures
  • Support implementation of data exploration analysis
  • Prepare final presentation to Commercialization Data Science & AI Predictive Solutions group

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, particularly in oncology, immunology, and cardiovascular health. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs that are affordable alternatives to their innovative medicines, ensuring they meet high safety and quality standards. What sets BMS apart from competitors is its dual focus on both innovative and generic medications, along with a strong commitment to sustainability and corporate responsibility. The company's goal is to improve patient outcomes by providing effective and affordable healthcare solutions while adhering to Environmental, Social, and Governance (ESG) principles.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1887

Simplify Jobs

Simplify's Take

What believers are saying

  • AI-driven drug discovery accelerates BMS's R&D, improving drug development efficiency.
  • BMS's acquisition of 2seventy bio enhances its cancer cell therapy capabilities.
  • Positive Phase 3 trial results for Sotyktu boost BMS's psoriatic arthritis treatment portfolio.

What critics are saying

  • Increased competition in oncology may impact BMS's market share.
  • Layoffs could decrease employee morale, affecting operational efficiency.
  • Integration challenges from acquiring 2seventy bio may pose financial risks.

What makes Bristol Myers Squibb unique

  • BMS focuses on oncology, immunology, and cardiovascular diseases, setting it apart in biopharma.
  • The company integrates AI in early lung cancer diagnosis, enhancing precision care.
  • BMS offers both innovative and generic medicines, increasing healthcare accessibility.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Company News

European HHHM
Apr 16th, 2025
Optellum Announces Agreement with Bristol Myers Squibb to Leverage AI to Boost Early Lung Cancer Diagnosis

Optellum, a global leader in AI-driven clinical decision support for early lung cancer diagnosis, has entered an agreement with Bristol Myers Squibb (NYSE: BMY), to leverage AI in early diagnosis and precision lung cancer care.

CMMB
Mar 24th, 2025
Our Values, Your Impact

In partnership with Bristol Myers Squibb, Catholic Medical Mission Board Inc. is playing a role in building the infrastructure and workforce to bring quality cancer care to rural Kenya.

PR Newswire
Mar 20th, 2025
Bristol Myers Squibb Appoints Osama Braiwish As General Manager For Saudi Arabia Gulf Countries

RIYADH, Saudi Arabia, March 20, 2025 /PRNewswire/ -- Bristol Myers Squibb, a leading global biopharmaceutical company, has recently appointed Osama Braiwish as its General Manager for Saudi Arabia and Gulf Countries, an affiliate covering Saudi Arabia, United Arab Emirates, Kuwait, Qatar, Oman, Bahrain, and Jordan

Investors Hangout
Mar 20th, 2025
Bristol Myers Squibb Welcomes New Leadership in Gulf Region

Bristol Myers Squibb, a leader in the global biopharmaceutical sector, has appointed Osama Braiwish as its General Manager for the Gulf region, thereby enhancing its capacity to serve medical needs across various specialties.

Business Wire
Mar 12th, 2025
2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb

2seventy bio, Inc. (Nasdaq: TSVT), today announced a definitive merger agreement under which Bristol Myers Squibb (NYSE: BMY) (“BMS”) will acquire all

INACTIVE